Paclitaxel and Mortality: The Dose Argument Is Critical

Abstract

Keywords

Dose effect drug-coated balloon drug-eluting stent drug-eluting technology femoropopliteal segment mortality paclitaxel

Get full access to this article

View all access options for this article.

References

Katsanos

Spiliopoulos

Kitrou

et al . Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.

Hill

AB.

The environment and disease: association or causation?

Proc R Soc Med. 1965;58:295-300.

Tallarida

Jacobs

. The Dose-Response Relation in Pharmacology. New York: Springer; 1979:1-17.

Hamada

Fujimichi

Classification of radiation effects for dose limitation purposes: history, current situation and future prospects. J Radiat Res. 2014;55:629-640.

Little

MP.

Risks associated with ionizing radiation. Br Med Bull. 2003;68:259-275.

The Food and Drug Administration (FDA). UPDATE: Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality - letter to health care providers. March 15, 2019. Available at: https://www.fda.gov/medical-devices/letters-health-care-providers/update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel-eluting. Accessed May 22, 2019.

Shulman

Berry

Cirrincione

et al . Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014;32:2311-2317.

Mayer

EL.

Use of paclitaxel as a primary therapy in oncology: outcomes, benefits, adverse events and doses compared to devices. Paper presented at VIVA Vascular Leaders Forum (VLF); March 1-2, 2019; Washington DC, USA.

Pignata

Scambia

Katsaros

et al . Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15:396–405.

10.

Freyhardt

Zeller

Kröncke

et al . Plasma levels following application of paclitaxel-coated balloon catheter in patients with stenotic, or occluded femoro-popliteal arteries. Röfo. 2011;183:448-455.

11.

Dake

MD.

Long-term safety information on paclitaxel-eluting stents: insights from the Zilver PTX program. Paper presented at LINC 2019; January 22-25, 2019; Leipzig, Germany.

12.

Schneider

Laird

Dorros

et al . Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis. J Am Coll Cardiol. 2019;73(20):2550-2563.

13.

Gray

. Patient safety in the Eluvia DES and Ranger DCB program. Abstract presented at LINC 2019; January 22-25, 2019; Leipzig, Germany.

14.

Lyden

. Long-term safety data from the Stellarex DCB program. Paper presented at LINC 2019; January 22-25, 2019; Leipzig, Germany.

15.

Albrecht

Schnorr

Kutschera

et al . Two-year mortality after angioplasty of the femoro-popliteal artery with uncoated balloons and paclitaxel-coated balloons-a pooled analysis of four randomized controlled multicenter trials. Cardiovasc Intervent Radiol. 2019 Mar 6. doi: 10.1007/s00270-019-02194-w.

16.

Schneider

Laird

Tepe

et al . Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11:e005891.

17.

Laird JR. 5-Year results from the IN.PACT SFA randomized trial. Paper presented at VIVA 2018; November 5-8, 2018; Las Vegas, NV, USA.

18.

Dake

Ansel

Jaff

et al ; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472-1483.

19.

Rosenfield

Jaff

White

et al ; LEVANT 2 Investigators. Trial of apaclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145-153.